{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:40:08Z","timestamp":1760366408014,"version":"build-2065373602"},"reference-count":74,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The study aimed to summarize clinical characteristics associated with Gallium-68-prostate-specific membrane antigen (PSMA) positron emission tomography\/computed tomography (68Ga-PSMA PET\/CT) scans as patients were restaged for prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or external beam radiotherapy (EBRT). Our analyses included multiple cox regression analyses. The study evaluated 95 patients with rising values of PSAs after RP and after EBRT. Sixty 63% of patients had a positive 68Ga-PSMA PET\/CT scan. Twelve patients (13%) had a positive site in the prostate bed, 29 patients (30%) had a positive site in the regional lymph nodes, and 19 (20%) had positive sites in distant organs. After four years follow-up, 21 patients (22%) died. Using multiple Cox regression analyses, the number of positive sites on the 68Ga-PSMA PET\/CT scan significantly predicted overall survival (OS) (p = 0.0001), whereas risk score and regional locations of the positive sites were not significant in the multiple Cox regression analyses. Our study indicates that the specific findings of 68Ga-PSMA PET\/CT scans are important because detailed findings of the scans predict the outcome after salvage treatment of patients with PSA relapse examined with 68Ga-PSMA PET\/CT scans.<\/jats:p>","DOI":"10.3390\/diagnostics11040622","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T09:57:04Z","timestamp":1617098224000},"page":"622","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["68Ga-PSMA PET\/CT for Patients with PSA Relapse after Radical Prostatectomy or External Beam Radiotherapy"],"prefix":"10.3390","volume":"11","author":[{"given":"Finn Edler","family":"von Eyben","sequence":"first","affiliation":[{"name":"Center of Tobacco Control Research, 5230 Odense, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6199-8551","authenticated-orcid":false,"given":"Cigdem","family":"Soydal","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ankara University, 06560 Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"von Eyben","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Stanford University, Stanford, CA 94350, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1464-410X.2011.10422.x","article-title":"The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: Long-term follow-up","volume":"109","author":"Antonarakis","year":"2012","journal-title":"BJU Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"JAMA"},{"key":"ref_3","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/(SICI)1097-0142(19991015)86:8<1557::AID-CNCR24>3.0.CO;2-2","article-title":"Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy","volume":"86","author":"Kestin","year":"1999","journal-title":"Cancer"},{"key":"ref_5","first-page":"S42","article-title":"Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy","volume":"172","author":"Moul","year":"2004","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S1470-2045(08)70236-5","article-title":"Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial","volume":"9","author":"Denham","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.eururo.2014.09.019","article-title":"Nomogram predicting prostate cancer-specific mortality for men with biochemical recurrence after radical prostatectomy","volume":"67","author":"Brockman","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2014.09.028","article-title":"The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy","volume":"67","author":"Zumsteg","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Avtzi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after rtadical prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective comparison of 18F-Fluoromethylcholine versus 68Ga-PSMA PET\/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/bju.13397","article-title":"68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment","volume":"117","author":"Stricker","year":"2016","journal-title":"BJU Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s00259-015-3240-1","article-title":"Extent of disease in recurrent prostate cancer determined by [68Ga] PSMA-HBED-CC PET\/CT in relation to PSA levels, PSA doubling time and Gleason score","volume":"43","author":"Verburg","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","article-title":"Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","article-title":"Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: Comparison with mpMRI integrated in simultaneous PET\/MRI","volume":"44","author":"Freitag","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"462","DOI":"10.23736\/S0393-2249.18.03081-3","article-title":"The role of 68Ga-PSMA PET\/CT scan in biochemical recurrence after primary treatment for prostate cancer: A systematic review of the literature","volume":"70","author":"Eissa","year":"2018","journal-title":"Minerva Urol. Nefrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.urology.2018.12.055","article-title":"Location of recurrence by Gallium-68 PSMA-11 PET scan in prostate cancer patients eligible for salvage radiotherapy","volume":"129","author":"Boreta","year":"2019","journal-title":"Urology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.18632\/oncotarget.27239","article-title":"The positivity rate of 68Gallium-PSMA-11 ligand PET\/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer","volume":"10","author":"Hoffmann","year":"2019","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ijrobp.2019.03.014","article-title":"A multicenter prospective clinical trial of 68Gallium PSMA HBED-CC PET-CT restaging in biochemically relapsed prostate carcinoma: Oligometastatic rate and distribution compared with standard imaging","volume":"104","author":"McCarthy","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2967\/jnumed.118.224543","article-title":"Intention-to-treat analysis of 68Ga-PSMA and (11)C-Choline PET\/CT versus CT for prostate cancer recurrence after surgery","volume":"60","author":"Schwenck","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10585-020-10043-1","article-title":"The clinical efficacy of PSMA PET\/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: Results of a single-centre, prospective clinical trial","volume":"37","author":"Joshi","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"73.e9","DOI":"10.1016\/j.urolonc.2020.07.010","article-title":"Evaluation of the clinical use of PET\/CT with 68Ga-PSMA for the assessment of biochemical recurrence of low or intermediate-risk prostate cancer","volume":"39","author":"Ribeiro","year":"2021","journal-title":"Urol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jfma.2020.07.029","article-title":"Comparison between 68Ga-PSMA-11 PET\/CT and multiparametric magnetic resonance imaging in patients with biochemically recurrent prostate cancer following robot-assisted radical prostatectomy","volume":"120","author":"Tseng","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pienta, K.J., Gorin, M.A., Rowe, S.P., Carroll, P.R., Pouliot, F., Probst, S., Saperstein, L., Preston, M.A., Alva, A.S., and Patnaik, A. (2021). A Phase 2\/3 Prospective multicenter study of the diagnostic accuracy of prostate-specific membrane antigen PET\/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J. Urol.","DOI":"10.1097\/JU.0000000000001698"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Morris, M.J., Rowe, S.P., Gorin, M.A., Saperstein, L., Pouliot, F., Josephson, D.Y., Wong, J.Y., Pantel, A.R., Cho, S.Y., and Gage, K.L. (2021). Diagnostic performance of 18F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: Results from the CONDOR phase 3, multicenter study. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-20-4573"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Afshar-Oromieh, A., da Cunha, M.L., Wagner, J., Haberkorn, U., Debus, N., Weber, W., Eiber, M., Holland-Letz, T., and Rauscher, I. (2021). Performance of [68Ga] Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-021-05189-3"},{"key":"ref_27","unstructured":"DAPROCA (2021, March 25). [Imaging of Prostate Cancer v 2.0] (Billiediagnostik ved Prostatacancer Version 2.0). Available online: www.daproca:billeddiagnostik_v2.0_pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: Treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gandaglia, G., Leni, R., Fossati, N., Cucchiara, V., Montorsi, F., and Briganti, A. (2021). Prostate-specific membrane antigen imaging in clinical guidelines: European Association of Urology, National Comprehensive Cancer Network, and beyond. Eur. Urol. Focus.","DOI":"10.1016\/j.euf.2020.12.014"},{"key":"ref_30","unstructured":"FDA FDA Approves First PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer, U.S. Food & Drug Administration."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.clgc.2018.05.014","article-title":"Comparison between 64Cu-PSMA-617 PET\/CT and 18F-Choline PET\/CT imaging in early diagnosis of prostate cancer biochemical recurrence","volume":"16","author":"Cantiello","year":"2018","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00345-018-2460-y","article-title":"68Ga-labelled PSMA ligand HBED-CC PET\/CT imaging in patients with recurrent prostate cancer","volume":"37","author":"Akdemir","year":"2019","journal-title":"World J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: A prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00259-020-04696-z","article-title":"Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET\/CT positivity in patients with prostate cancer recurrence and PSA <1 ng\/mL external validation on a single institution database","volume":"47","author":"Bianchi","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s00259-019-04505-2","article-title":"Prediction nomogram for 68Ga-PSMA-11 PET\/CT in different clinical settings of PSA failure after radical treatment for prostate cancer","volume":"47","author":"Ceci","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/JU.0000000000001012","article-title":"Optimal timing of prostate specific membrane antigen positron emission tomography\/computerized tomography for biochemical recurrence after radical prostatectomy","volume":"204","author":"Luiting","year":"2020","journal-title":"J. Urol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2967\/jnumed.120.261834","article-title":"Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler about FDA approval of PSMA","volume":"62","author":"Sartor","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","article-title":"Impact of 68Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial","volume":"61","author":"Fendler","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.119.237602","article-title":"Impact of 68Ga-PSMA-11 PET\/CT on staging and management of prostate cancer patients in various clinical settings: A prospective single-center Study","volume":"61","author":"Sonni","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"226","DOI":"10.23736\/S1824-4785.18.03056-X","article-title":"Predictor of 68Ga PSMA PET\/CT positivity in patients with prostate cancer","volume":"64","author":"Soydal","year":"2020","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e22693","DOI":"10.1002\/jcla.22693","article-title":"Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: Towards risk adapted follow-up","volume":"33","author":"Grivas","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2967\/jnumed.115.158550","article-title":"68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept Human Studies","volume":"56","author":"Weineisen","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: Definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Whittington","year":"1998","journal-title":"JAMA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","article-title":"Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes","volume":"177","author":"Cookson","year":"2007","journal-title":"J. Urol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_48","unstructured":"(2018, February 01). Memorial Sloan Kettering Cancer Center. Available online: https:\/\/www.mskcc.org\/nomograms\/prostate\/psa_doubling_time."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate cancer molecular imaging standardized evaluation (PROMISE): Proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S1470-2045(18)30571-0","article-title":"Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: A consensus recommendation from the EORTC Imaging Group","volume":"19","author":"Lecouvet","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s12094-020-02427-2","article-title":"Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET\/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series","volume":"23","author":"Francolini","year":"2021","journal-title":"Clin. Transl. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00259-019-04643-7","article-title":"The management impact of 68gallium-tris(hydroxypyridinone) prostate-specific membrane antigen (68Ga-THP-PSMA) PET-CT imaging for high-risk and biochemically recurrent prostate cancer","volume":"47","author":"Kulkarni","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e13063","DOI":"10.1111\/eci.13063","article-title":"Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: A meta-analysis","volume":"49","author":"Treglia","year":"2019","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00259-018-4249-z","article-title":"Impact of Ga-68-PSMA PET\/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy","volume":"46","author":"Bashir","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1097\/MNM.0000000000000749","article-title":"Comparison of 68Ga-PSMA PET\/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer","volume":"38","author":"Tulsyan","year":"2017","journal-title":"Nucl. Med. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.2967\/jnumed.117.196683","article-title":"Treatment outcomes from 68Ga-PSMA PET\/CT-informed salvage radiation treatment in men with rising PSA after radical prostatectomy: Prognostic value of a negative PSMA PET","volume":"58","author":"Emmett","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-020-04914-8","article-title":"Clinical value of negative 68Ga-PSMA PET\/CT in the management of biochemical recurrent prostate cancer patients","volume":"48","author":"Celli","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000481438","article-title":"Management of biochemical recurrence after primary curative treatment for prostate cancer: A review","volume":"100","author":"Artibani","year":"2018","journal-title":"Urol. Int."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-year freedom from progression after 68Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: Results of a prospective multicenter trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: Results of an australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.1158\/1078-0432.CCR-20-0587","article-title":"A Prospective trial of 68Ga-PSMA and 18F-FDG PET\/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration","volume":"26","author":"Wang","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE Phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2018.04.017","article-title":"Stereotactic body radiotherapy for oligometastatic prostate cancer detected via prostate-specific membrane antigen positron emission tomography","volume":"1","author":"Kneebone","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: A prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer\u2014The SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1007\/s00345-020-03131-0","article-title":"68Ga-PSMA PET\/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy","volume":"38","author":"Kopp","year":"2020","journal-title":"World J. Urol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Calais, J., Czernin, J., Fendler, W.P., Elashoff, D., and Nickols, N.G. (2019). Randomized prospective phase III trial of 68Ga-PSMA-11 PET\/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer, 19.","DOI":"10.1186\/s12885-018-5200-1"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A prospective study on 18F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Evangelista, L., Zattoni, F., Cassarino, G., Artioli, P., Cecchin, D., Dal Moro, F., and Zucchetta, P. (2020). PET\/MRI in prostate cancer: A systematic review and meta-analysis. Eur. J. Nucl. Med. Mol. Imaging.","DOI":"10.1007\/s00259-020-05025-0"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/4\/622\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:10:30Z","timestamp":1760364630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/4\/622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":74,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["diagnostics11040622"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11040622","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}